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OBJECTIVES We studied the impact of the angiotensin-converting enzyme (ACE)/DD genotype on
morphologic and functional cardiac changes in adult endurance athletes.
BACKGROUND Trained athletes usually develop adaptive left ventricular hypertrophy (LVH), and ACE gene
polymorphisms may regulate myocardial growth. However, little is known about the impact
of the ACE/DD genotype and D allele dose on the cardiac changes in adult endurance
athletes.
METHODS Echocardiographic studies (including tissue Doppler) were performed in 61 male endurance
athletes ranging in age from 25 to 40 years, with a similar period of training (15.6 4 h/week
for 12.6  5.7 years). The ACE genotype (insertion [I] or deletion [D] alleles) was
ascertained by polymerase chain reaction (DD 27, ID 31, and II 3). Athletes with the
DD genotype were compared with their ID counterparts.
RESULTS The DD genotype was associated with a higher left ventricular mass index (LVMI) than the
ID genotype (162.6  36.5 g/m2 vs. 141.6  34 g/m2, p  0.031), regardless of other
confounder variables. As a result, 70.4% of DD athletes and only 42% of ID athletes met the
criteria for LVH (p 0.037). Although systolic and early diastolic myocardial velocities were
similar in DD and ID subjects, a more prolonged E-wave deceleration time (DT) was
observed in DD as compared with ID athletes, after adjusting for other biologic variables (210
 48 ms vs. 174  36 ms, respectively; p  0.008). Finally, a positive association between
DT and myocardial systolic peak velocity (medial and lateral peak Sm) was only observed in
DD athletes (p  0.013, r  0.481).
CONCLUSIONS The ACE/DD genotype is associated with the extent of exercise-induced LVH in endurance
athletes, regardless of other known biologic factors. (J Am Coll Cardiol 2003;42:527–32)
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Adaptive left ventricular hypertrophy (LVH) is a well-
known feature of the athlete’s heart (1). Physical exercise
activates the renin-angiotensin system (RAS) (2), and this
system may regulate myocardial growth (2,3). Indeed, an-
giotensin II stimulates cardiac protein synthesis, whereas
bradykinins may have an antiproliferative effect. The
angiotensin-converting enzyme (ACE) is a key enzyme in
the production of angiotensin II, as well as degradation of
bradykinins, and it may modulate cardiac growth. Thus, an
upregulated RAS after a long period of training may
contribute to ventricular mass growth. However, not all
endurance athletes with similar training develop left ven-
tricular (LV) mass growth to the same extent, suggesting
that genetic factors may modulate heart size (4).
Genes encoding RAS components regulate ACE levels
and angiotensin II expression and function (5). In particu-
lar, an insertion/deletion (I/D) polymorphism of the ACE
gene affects the plasma and tissue levels of ACE activity.
The presence of each D allele has an additive effect on ACE
levels, so that DD subjects have the highest levels of this
enzyme (6). Therefore, a positive association between the D
allele dose and exercise-induced hypertrophy appears likely.
Despite this evidence, the role of the ACE/DD genotype
in the development of the athlete’s heart is unclear. Pro-
spective and cross-sectional studies have found a prepon-
derance of D allele carriers among individuals with exercise-
induced cardiac changes, but a D allele dose effect was not
demonstrated. Indeed, significant cardiac growth in re-
sponse to physical training (7–9) and established exercise-
induced LVH (10) were similarly achieved by both DD and
ID subjects. Other reports, however, have not observed such
an association (11,12). Additionally, some studies included
athletes younger than 20 years (8,12), and it is known that
the most pronounced and homogeneous cardiac changes
induced by exercise occur among elite athletes (13) or
endurance athletes ranging in age from 20 to 39 years (14).
Thus, the impact of the ACE/DD genotype and D allele
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dose on heart size could be greater in adult endurance
athletes who have undergone vigorous training programs
over longer periods. Finally, little information has been
provided about Doppler-derived diastolic function in these
subjects (7–12), which could distinguish pathologic from
physiologic LVH (15,16).
We investigated the effect of the ACE/DD genotype on
morphologic and functional cardiac changes, assessed by
echocardiography, in 61 male endurance athletes (age range
25 to 40 years) with long periods of intensive training.
METHODS
Study population. A group of 61 white male endurance
athletes from the Canary Islands were studied. All of them
participated primarily in isotonic sports (36 long- and
middle-distance runners, 4 swimmers, 11 endurance cy-
clists, and 10 triathlonists). Each athlete had trained for at
least 10 h/week for the last 5 years (15.6  4 h/week for
12.6  5.7 years). None of the athletes had a history of
cigarette smoking, hypertension, coronary artery disease,
diabetes mellitus, renal or hepatic dysfunction, or a positive
family history of hypertrophic cardiomyopathy. Likewise,
no medication was taken by any of the athletes for any
reason, including anabolic steroids. Blood pressure was
measured in a sitting position from the right arm after 15
min of rest. Mean systolic blood pressure was 117 12 mm
Hg (range 140 to 90 mm Hg), and mean diastolic blood
pressure was 65  7 mm Hg (range 50 to 80 mm Hg).
This study was approved by the Ethics Committee of the
Hospital Universitario and conducted according to the
Declaration of Helsinki. All athletes gave written, informed
consent before participating in the study.
Laboratory measurements. Fasting biochemical parame-
ters (serum creatinine, glucose, and complete blood count)
were measured by means of a computerized autoanalyzer
(Hitachi 717, Boehringer Mannheim, Mannheim,
Germany).
Echocardiographic methods. Echocardiographic studies
were performed with an ultrasonoscope system equipped
with a tissue Doppler program (Hewlett-Packard Sonos
5500 Advanced Diagnostics, Palo Alto, California), using a
2- to 4-MHz multifrequency transducer. Echocardiograms
were recorded following a standard protocol at or just below
the tips of the mitral valve leaflets, with the transducer
applied to the third or fourth intercostal space. All mea-
surements were analyzed by two experienced readers (A.R.
and A.B.), on an average of three to five cardiac cycles,
without previous knowledge of the genetic typing. In our
laboratory, interobserver variability for these measurements
was below 7%, similar to previous results from our labora-
tory (17).
Standard echocardiographic studies consisted of M-mode,
two-dimensional, and Doppler blood flow measurements.
Cavities and cardiac walls were measured following the
recommendations of the American Society of Echocardiog-
raphy (18). Left ventricular mass was determined according
to the method of Devereux and Reichek (19) and indexed to
body surface area to yield the left ventricular mass index
(LVMI). The cut-off level defining LVH was LVMI 143
g/m2 (20). Systolic function was assessed by the ejection
fraction. Pulsed-wave Doppler of transmitral flow was used
to assess overall diastolic function. The Doppler indexes
measured were peak early velocity (E) and peak atrial
velocity (A) in centimeters per second, deceleration time of
the E-wave (DT), and LV isovolumic relaxation time (ms).
In addition, the E/A ratio was calculated.
Pulsed-wave tissue Doppler echocardiography was per-
formed from the apical four-chamber view for lateral and
medial sites. The sample volume (gated at 5 mm) was placed
over the mitral annulus when the patient was breathing
normally. Peak velocities of the medial and lateral mitral
annulus were acquired. Filters were set to exclude high-
frequency signals, and the Nyquist limit was adjusted to a
velocity range of 15 to 20 cm/s. Thus, the following
measurements were obtained: peak velocity of the myocar-
dial systolic wave (peak Sm [cm/s]), peak velocity of the
E-wave (peak Em [cm/s]), and peak velocity of the A-wave
(peak Am [cm/s]). The Em/Am ratio was calculated.
Determination of genotypes. The ACE I/D polymor-
phism was determined by polymerase chain reaction ampli-
fication of a fragment of intron 16 of the ACE gene (21).
Deoxyribonucleic acid (DNA) was purified from 3 ml blood
by proteinase K digestion, phenol extraction, and ethanol
precipitation, following standard protocols. Approximately
0.1 g DNA was amplified with specific primers, and the
amplification product was analyzed by gel electrophoresis.
Samples yielding exclusive amplification of the D allele (and
therefore potentially typed as DD) were subjected to a
second independent amplification, as described by Lind-
paintner et al. (21). We also estimated the genotype
frequencies for the I/D polymorphism at the ACE locus
among 246 DNA samples from nonathletic healthy indi-
viduals, which have been previously reported (22).
Statistical analysis. Differences in the distribution of ACE
genotypes between the athletes and healthy individuals was
tested by the chi-square exact test. A comparison between
the genotypes observed and the predictions from the Hardy-
Weinberg model was also done by chi-square analysis.
Likewise, frequencies of DD and ID genotypes with LVH
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
D  deletion
DNA  deoxyribonucleic acid
DT  deceleration time of the E-wave
I  insertion
LV  left ventricular
LVH  left ventricular hypertrophy
LVMI  left ventricular mass index
peak Sm  myocardial systolic peak velocity
RAS  renin-angiotensin system
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were evaluated by the chi-square test. Given that only three
subjects were homozygous for the I allele, we statistically
compared DD and ID genotypes. Thus, comparisons of
continuous variables between both groups were performed
by the t test. General factorial analysis of covariance was
used to compare LVMI, as well as DT, between DD and ID
genotypes, after adjusting for other potential confounding
variables. Linear regression analysis was used to correlate
quantitative echocardiographic parameters with different
clinical and biochemical data. All data are expressed as the
mean value  SD. A p value 0.05 was considered
significant, and all p values are two-tailed. All computations
were made using the statistical package SPSS version 10.0
for Windows (SPSS Inc., Chicago, Illinois). Exact tests
were performed by Statxact version 5.0 (Cytel Software Co.,
Cambridge, Massachusetts).
RESULTS
All samples typed as DD with the first assay (primer hace3s
and hace3as) were confirmed to lack the I allele by using the
second assay (primers hace5a and hace5c), and no disagree-
ment was found between both assays. This is consistent with
previous experience in our laboratory, as long as purified
DNAs, rather than cell lysates, are used as a template for the
amplification reaction. The distribution of the DD, ID, and
II genotypes in athletes was 44% (n  27), 51% (n  31),
and 5% (n  3), respectively. For the 246 samples from
nonathletic healthy individuals tested in our laboratory, the
following frequencies for DD, ID, and II were obtained:
37.8%, 49.2%, and 13%, respectively. These differences in
genotype frequencies were not statistically significant (chi-
square  3.354, p  0.187).
Table 1 shows the characteristics and biochemical data of
endurance athletes according to ACE gene polymorphism.
To assess the impact of the D allele dose on cardiac changes,
individuals with the DD genotype were compared with
those with the ID genotype. There were no significant
differences with regard to body mass index, years of active
competitive sports, endurance training (h/week), heart rate,
hemoglobin levels, and systolic and diastolic blood pressure
between the groups, although ID subjects showed a ten-
dency toward a higher age and serum creatinine than DD
athletes (Table 1). Morphologic echocardiographic data are
summarized in Table 2. Interestingly, DD athletes showed
Table 1. Characteristics and Biochemical Data for Endurance Athletes According to
Angiotensin-Converting Enzyme Gene Polymorphism
DD (n  27) ID (n  31) II (n  3) p Value*
Age (yrs) 30.5  4.5 32.5  4.5 29.3  7.5 0.099
Height (cm) 173.6  5.4 175.3  5.4 178.3  8 0.241
Weight (kg) 67  6 70.2  8.3 69  7 0.103
Body mass index (kg/m2) 22.2  1.6 22.8  1.8 21.6  0.3 0.227
Training (h/week) 15.6  4.2 15.4  4 16.3  3.2 0.845
Training (yrs) 12.7  5.4 13  6 7.7  2 0.846
Rest heart rate (beats/min) 53  7.7 51.6  7.8 57.3  7.7 0.479
Systolic blood pressure (mm Hg) 118.6  7.5 117.2  14.3 101.6  2.8 0.656
Diastolic blood pressure (mm Hg) 65.2  7.7 64.8  7.7 58.3  3 0.864
Hemoglobin level (g/l) 146  7 149  9 149  4 0.157
Hematocrit fraction of 1.00 0.43  0.02 0.44  0.02 0.44  0.06 0.180
Serum glucose (mmol/l) 4.5  0.7 4.4  0.7 3.9  0.2 0.498
Serum creatinine (mol/l) 82.6  10.6 90.4  18.4 91.3  13.5 0.062
*DD vs. ID athletes. Data are presented as the mean value  SD.
Table 2. Morphological Echocardiographic Data
DD (n  27) ID (n  31) II (n  3) p Value*
LVESD (mm) 32.7  4.2 31.9  5.2 31.3  2.3 0.556
LVEDD (mm) 52.8  5.1 51.2  5.2 51.8  5.2 0.224
LAD (mm) 38  4.6 37.7  6 37  1 0.828
LVEF (%) 67.8  5.8 65.5  8.9 69  7.2 0.263
IVST (mm) 12.3  1.7 11.7  2.2 9.9  1 0.288
PWT (mm) 11  1.3 10.5  1.7 10.7  0.5 0.442
LVM (g) 294.6  72 262  64 236.9  25 0.074
LVMI† (g/m2)
Unadjusted 162.6  36 141.5  34 127.8  17 0.025
Adjusted 162.2  36.5 141.6  34 127.7  17.5 0.031
Subjects with LVH 19 (70.4%) 13 (42%) 0 0.037
*DD vs. ID athletes. †Data on LVMI are presented in unadjusted form and adjusted for age, years of training, hemoglobin levels, body mass index and systolic and diastolic blood
pressure. Data are presented as the mean value  SD or number (%) of subjects.
IVST  interventricular septal thickness; LAD  left auricular diameter; LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular ejection fraction;
LVESD  left ventricular end-systolic diameter; LVH  left ventricular hypertrophy; LVM  left ventricular mass; LVMI  left ventricular mass index; PWT  posterior
wall thickness.
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a significantly greater LVMI than ID athletes, even after
adjusting for age, body mass index, hemoglobin levels, years
of training, and blood pressure. As a result, 70.4% of DD
athletes and only 42% of ID athletes met the criteria for
LVH (chi-square  4.71, p  0.037). None of the subjects
with the II genotype showed echocardiographic data of
cardiac hypertrophy.
Table 3 shows standard and tissue Doppler echocardio-
graphic measurements in athletes with the DD, ID, and II
genotype. Although systolic and early diastolic myocardial
velocities were similar in DD or ID individuals, the DT was
significantly more prolonged in DD athletes (Table 3). This
difference persisted after adjusting for confounding variables
such as age, heart rate, LVMI, and time of training (Fig. 1,
Table 3). Other diastolic parameters were not different
between DD and ID subjects. Finally, a significant corre-
lation between DT and myocardial systolic peak velocity
(medial and lateral peak Sm) was only observed in DD
athletes (p  0.013, r  0.481). No other associations were
found between echocardiographic parameters and clinical
data.
DISCUSSION
This study demonstrates that the ACE/DD genotype is
associated with the development of exercise-induced cardiac
growth in endurance athletes. As a result, a different
diastolic filling pattern, as evidenced by a longer DT, was
also present in these subjects.
The ACE genotype has been associated with cardiac
growth in the presence of several pathologic processes
(5,22), but this does not permit one to definitely conclude
that this polymorphism mediates the development of LVH.
Thus, for a better understanding of the role of this poly-
morphism on cardiac growth, we only included male endur-
ance athletes (age range 25 to 40 years) after a long and
intensive period of training. Additionally, we explored
diastolic function in our athletes by using standard and
tissue Doppler echocardiography to distinguish pathologic
from physiologic LVH. Under these conditions, the effect of
genetic factors might be more evident than was previously
assumed, and it could clarify the contribution of this
polymorphism to the development of LVH.
Synthesis of several RAS components, including ACE,
Figure 1. The E-wave deceleration time (DT) in DD and ID individuals.
Data are presented in adjusted form for age, heart rate, years of training,
and left ventricular mass index. p  0.008 for DD vs. ID. ACE 
angiotensin-converting enzyme.
Table 3. Standard and Tissue Doppler Echocardiographic Measurements in Athletes With DD, ID, and II Genotype
DD (n  27) ID (n  31) II (n  3) p Value*
Standard Doppler
Peak E (cm/s) 79  16 80  19 70.4  7 0.815
Peak A (cm/s) 43  11 46  8.7 45.5  10 0.271
E/A ratio 1.9  0.4 1.8  0.5 1.6  0.6 0.365
DT (ms)
Unadjusted 213  49 174  35 185  52 0.001
Adjusted 210  32 174.1  36 185  52.1 0.008
LVIRT (ms) 97  10.4 98  19 106  6 0.801
Tissue Doppler imaging
Lateral
Peak Em (cm/s) 18.3  3.8 17.7  4 16.2  4 0.556
Peak Am (cm/s) 7.8  2 8.8  3.7 6.8  0.3 0.261
Em/Am ratio 2.5  0.8 2.3  1 2.4  0.7 0.471
Peak Sm (cm/s) 11.8  4.5 11.5  2.8 8  1.9 0.733
E/Em ratio 4.5  1.2 4.6  1.3 4.5  1.2 0.570
Medial
Peak Em (cm/s) 12.5  2.4 12.4  2.5 11  3.2 0.871
Peak Am (cm/s) 8  1.5 8.7  1.7 8  1.2 0.178
Em/Am ratio 1.6  0.4 1.5  0.3 1.4  0.4 0.220
Peak Sm (cm/s) 9.2  3 9.1  1.4 8.1  0.9 0.845
E/Em 6.5  1.9 6.5  1.6 6.7  1.8 0.965
*DD vs. ID athletes. Data are presented as the mean value  SD.
DT  deceleration time of E wave; LVIRT  left ventricular isovolumetric relaxation time; Peak A  peak of late diastolic flow velocity; peak Am  peak of myocardial
late diastolic wave; peak E  peak of early diastolic flow velocity; peak Em  peak of myocardial early diastolic wave; peak Sm  myocardial systolic peak velocity.
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has been shown to take place in the myocardium and to be
upregulated during myocardial growth (3). Angiotensin-
converting enzyme is a key enzyme in the production of
angiotensin II, as well as the degradation of bradykinins,
and it may therefore participate in cardiac growth. Physical
exercise activates the RAS, resulting in an increase of
angiotensin II levels (2). Thus, a physiologic role of RAS in
the development of the athlete’s heart appears likely. How-
ever, the degree to which LV mass changes in response to
exercise is highly variable, suggesting that genetic factors
may play an important role in this process.
An I/D polymorphism of the ACE gene, located in the
noncoding region of the gene (intron 16), affects the plasma
and tissue levels of ACE activity. Normal individuals
homozygous for the D allele show the highest plasma and
tissue ACE levels (6), including the heart (23). Thus,
healthy subjects with the DD genotype may have a higher
risk of LVH than subjects with other genotypes (ID or II)
(24). High-performance athletes seem to be an ideal pop-
ulation to study the possible association between ACE
polymorphism and the athlete’s heart, as adaptive LVH is
very common in endurance athletes (1). Thus, during
top-level training, genetically increased ACE activity might
influence local tissue angiotensin II generation, thereby
stimulating cardiac growth. In other words, the ACE/DD
polymorphism may play a permissive role in the develop-
ment of LVH when the cardiac growth machinery is
activated. Accordingly, endurance athletes being homozy-
gous for the D allele may potentially have a higher risk than
ID or II subjects of developing significant LVH after a long
period of training.
In agreement with these arguments, our endurance ath-
letes with the DD genotype showed a higher LV mass than
those with the ID genotype, after a similar intensive training
regimen. We statistically compared echocardiographic data
from DD and ID subjects, because only three subjects were
homozygous for the I allele; nevertheless, none of the II
individuals met criteria for LVH, as previously reported
(7,8). The effect of the DD genotype was independent of
other known biologic factors that affect cardiac growth, as
documented in normal individuals (25). This suggests that
ACE may be a rate-limiting step in tissue angiotensin II
generation or degradation of kinins, when a greater D allele
dose and intensive training concur. This mechanism might
also explain the reported interaction of a polymorphism at
the bradykinin receptor B2BKR (26). In any case, this
positive association does not definitely prove a direct bio-
logic effect of this polymorphism on the athlete’s heart, and,
obviously, larger studies will be required to confirm this
issue.
Prospective studies have found a preponderance of D
allele carriers who have experienced exercise-induced car-
diac changes, but no effect of the D allele dose was
demonstrated. In fact, significant cardiac growth in response
to physical training was similarly achieved in both DD and
ID subjects (7–9). Likewise, in a cross-sectional study, LV
mass was not different between DD and ID athletes (10).
Other investigators, however, have not observed such an
association (11,12). There are several possible reasons for
the differences between these reports and our study. First,
most studies that previously investigated this association
included athletes younger than 20 years (8,12), and it is
known that the most pronounced exercise-induced cardiac
changes take place in elite, adult athletes (13). Moreover,
more uniform cardiac growth has been reported in endur-
ance athletes ranging in age from 20 to 39 years (14). Thus,
the impact of the ACE/DD genotype and D allele dose on
cardiac growth might have been underestimated in previous
studies. Finally, LVH is a multifactorial process and may be
influenced by ethnic heterogeneity or population stratifica-
tion, among others factors.
Previous reports have demonstrated a normal diastolic
filling pattern in exercise-induced cardiac growth (15,27),
but in most of them, the genetic influence of RAS on
diastolic function was not documented. The higher avail-
ability of local angiotensin II in DD subjects could mediate
changes in diastolic properties. Several criteria have been
proposed to distinguish exercise-induced from pathologic
hypertrophy, including reversal of the E/A ratio, prolonga-
tion of the DT, and/or a lesser systolic annular peak
velocity, among others (16,28). Our DD athletes had a
longer DT than their ID counterparts, but tissue Doppler
systolic and diastolic velocities, which most accurately dis-
tinguish physiologic from pathologic LVH (16), were sim-
ilar in both groups. Angiotensin II leads to prolonged
diastolic filling (29), so that an early diastolic change might
be expected in DD athletes with LVH. However, angio-
tensin II–induced myocardial hypercontractility, which en-
hances diastolic myocardial elastic recoil, may balance this
effect, providing a proper LV filling and stroke volume in
these subjects. In favor of this view was the finding of a
positive correlation between DT and peak Sm only in DD
athletes.
Recent studies have shown higher frequencies of the I
allele among endurance athletes (30). However, there have
been conflicting reports about this association, and the
representation of ACE alleles among elite athletes might
vary depending on the type of sports activity (31). The trend
toward a lower frequency of I alleles found in our sample of
athletes was not statistically significant, and it could be
merely due to chance.
The DD genotype has been associated with a variety of
adverse cardiovascular effects (5), and LVH is an indepen-
dent predictor for the development of heart failure in the
general population (32). Whether exercise-induced cardiac
growth also carries an increased risk of sudden death in DD
endurance athletes is of great concern. The long-term effect
of ACE polymorphism on the athlete’s heart requires
futures studies to answer this important question.
Study limitations. There are several potential limitations
of this study. Genetic association studies may only provide
hypotheses rather than proof for a biologic effect. Thus, a
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molecular marker of exercise-induced cardiac growth ap-
pears to be rather limited, unless we understand the mech-
anism whereby angiotensin II increases LV mass. In addi-
tion, we could not rule out other genetic mutations
responsible for hypertrophic cardiomyopathy in our study.
However, the absence of this disorder in family members of
our DD subjects makes this unlikely. Finally, we have no
data on our athletes’ heart size before they initiated system-
atic and long-term training. Future longitudinal and pro-
spective studies will be needed to clarify the prognostic
significance of ACE I/D polymorphism on the athlete’s
heart.
Conclusions. The ACE/DD genotype is associated with
the extent of exercise-induced LV growth in adult endur-
ance athletes, regardless of other known biologic factors.
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